Background The production of peroxide and superoxide is an inevitable consequence of
aerobic metabolism, and while these particular'reactive oxygen species'(ROSs) can exhibit a …

In the light of the enthusiasm regarding the use of recombinant human erythropoietin (Epo)
and its analogues for treatment of the anaemias of chronic renal failure and malignancies it …

Anemia is a potential nontraditional risk factor for cardiovascular disease (CVD). This study
evaluated whether anemia is a risk factor for adverse outcomes in people with diabetes and …

Hemoglobin cycling in hemodialysis patients treated with recombinant human
erythropoietin. Background Treatment with recombinant human erythropoietin (rHuEPO) has …

The cytokine erythropoietin (EPO) protects the heart from ischemic injury, in part by
preventing apoptosis. However, EPO administration can also raise the hemoglobin …

Background—Doxorubicin is a highly effective antineoplastic drug, but its clinical use is
limited by its adverse side effects on the heart. We investigated possible protective effects of …

Tissue hypoxia is the major stimulus of erythropoietin (EPO) synthesis in fetuses and adults.
Since EPO does not cross the placenta and is not stored, fetal plasma and amniotic fluid …

Administration of human recombinant erythropoietin (EPO) at time of acute ischemic renal
injury (IRI) inhibits apoptosis, enhances tubular epithelial regeneration, and promotes renal …

Many hematopoietic growth factors are produced locally in the brain. Among these,
erythropoietin (Epo), has a dominant role for neuroprotection, neurogenesis, and acting as a …

Objectives Late treatment with erythropoietin (EPO), as well as the administration before the
onset of or during the acute stage of myocardial infarction (MI), has recently been shown to …